IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v2y2018i2d10.1007_s41669-017-0050-3.html
   My bibliography  Save this article

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis

Author

Listed:
  • Bernard Charbonnel

    (Hôtel Dieu Hospital)

  • Dominique Simon

    (Pitié Hospital)

  • Jean Dallongeville

    (INSERM-U1167)

  • Isabelle Bureau

    (Cemka-Eval)

  • Sylvie Dejager

    (Merck Sharpe & Dohme)

  • Laurie Levy-Bachelot

    (Merck Sharpe & Dohme)

  • Julie Gourmelen

    (INSERM UMS 011)

  • Bruno Detournay

    (Cemka-Eval)

Abstract

Objectives Our objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013. Methods Data were drawn from a random sample of ≈600,000 patients registered in the French national health insurances database, which covers 90% of the French population. An algorithm was used to select patients with T2DM. Direct healthcare costs from a collective perspective were derived from the database and compared with those from a control group to estimate the cost of diabetes and related comorbidities. Overall direct costs were also compared according to the diabetes therapies used throughout the year 2013. Results Cost analysis was available for a sample of 25,987 patients with T2DM (mean age 67.5 ± standard deviation 12.5; 53.9% male) matched with a control group of 76,406 individuals without diabetes. Overall per patient per year medical expenditures were €6506 ± 10,106 in the T2DM group as compared with €3668 ± 6954 in the control group. The cost difference between the two groups was €2838 per patient per year, mainly due to hospitalizations, medication and nursing care costs. Total per capita annual costs were lowest for patients receiving metformin monotherapy (€4153 ± 6170) and highest for those receiving insulin (€12,890). However, apart from patients receiving insulin, costs did not differ markedly across the different oral treatment patterns. Conclusion Extrapolating these results to the whole T2DM population in France, total direct costs of diagnosed T2DM in 2013 was estimated at over €8.5 billion. This estimate highlights the substantial economic burden of this condition on society.

Suggested Citation

  • Bernard Charbonnel & Dominique Simon & Jean Dallongeville & Isabelle Bureau & Sylvie Dejager & Laurie Levy-Bachelot & Julie Gourmelen & Bruno Detournay, 2018. "Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis," PharmacoEconomics - Open, Springer, vol. 2(2), pages 209-219, June.
    • Handle: RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0050-3
    DOI: 10.1007/s41669-017-0050-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-017-0050-3
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-017-0050-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. J. Pöhlmann & K. Norrbacka & K. S. Boye & W. J. Valentine & H. Sapin, 2020. "Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1179-1196, November.
    2. Claudiu Morgovan & Smaranda Adina Cosma & Madalina Valeanu & Anca Maria Juncan & Luca Liviu Rus & Felicia Gabriela Gligor & Anca Butuca & Delia Mirela Tit & Simona Bungau & Steliana Ghibu, 2020. "An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System," IJERPH, MDPI, vol. 17(12), pages 1-16, June.
    3. Viera Ivanková & Rastislav Kotulič & Jaroslav Gonos & Martin Rigelský, 2019. "Health Care Financing Systems and Their Effectiveness: An Empirical Study of OECD Countries," IJERPH, MDPI, vol. 16(20), pages 1-22, October.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0050-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.